Trial: 202106106

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab.

Phase

II (Cancer Control)

Principal Investigator

Thaker, Premal

Disease Site

Other Female Genital; Ovary; Soft Tissue

Learn more about this study at: clinicaltrials.gov